Medical cost and treatment outcome related factors for HCC
碩士 === 國立中山大學 === 醫務管理研究所 === 94 === Background: Hepatocellular carcinoma (HCC) is the leading cause of cancer in Taiwan, which consumes high medical expense among the total healthcare expenditure and becomes the significant burden to the finance of National Health Insurance (NHI). However, populati...
Main Authors: | Ching-Fen Huang, 黃竫棻 |
---|---|
Other Authors: | Hsin-Chia Hung |
Format: | Others |
Language: | zh-TW |
Published: |
2005
|
Online Access: | http://ndltd.ncl.edu.tw/handle/80966148963302474921 |
Similar Items
-
How to improve HCC surveillance outcomes
by: Morris Sherman
Published: (2019-12-01) -
Impact of diabetes mellitus on outcome of HCC
by: Deepak N. Amarapurkar, et al.
Published: (2008-04-01) -
A Study on The Out-of-pocket Mental Health-related Medical Market
by: Chi-Fen Huang, et al.
Published: (2018) -
Immune Checkpoint Inhibitors in the Treatment of HCC
by: Clelia Donisi, et al.
Published: (2021-01-01) -
Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
by: Chen, L., et al.
Published: (2022)